Analyst Price Targets — VVOS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 17, 2026 1:45 pm | — | H.C. Wainwright | $2.50 | $1.01 | TheFly | Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright |
| April 17, 2026 12:26 pm | — | Industrial Alliance Securities | $1.75 | $1.00 | TheFly | Vivos Therapeutics price target lowered to $1.75 from $2.50 at Alliance Global |
| May 20, 2025 11:03 am | Scott Henry | Industrial Alliance Securities | $2.25 | $2.15 | TheFly | Vivos Therapeutics downgraded to Neutral from Buy at Alliance Global Partners |
Latest News for VVOS
Vivos Therapeutics (NASDAQ: VVOS) executives told investors the company's shift toward a medical provider-focused model, anchored by the June 2025 acquisition of the Sleep Center of Nevada (SCN), drove higher revenue in 2025 and is reshaping its growth strategy heading into 2026. 2025 results reflect SCN acquisition and model pivot Chief Financial Officer Bradford Amman said
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the…
LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), announced it plans to release its full year 2025 financial results after market close today,…
Vivos Therapeutics, Inc. (NASDAQ: VVOS - Get Free Report) was the target of a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 316,118 shares, a decline of 34.7% from the March 15th total of 484,373 shares. Approximately 3.1% of the shares of the stock are
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VVOS.
U.S. House Trading
No House trades found for VVOS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.